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System-based proteomic and metabonomic analysis of the
Df(16)A+/− mouse identiﬁes potential miR-185 targets and
molecular pathway alterations
H Wesseling1, B Xu2, EJ Want3, E Holmes3, PC Guest1, M Karayiorgou2, JA Gogos4,5 and S Bahn1,6
Deletions on chromosome 22q11.2 are a strong genetic risk factor for development of schizophrenia and cognitive dysfunction. We
employed shotgun liquid chromatography–mass spectrometry (LC-MS) proteomic and metabonomic proﬁling approaches on
prefrontal cortex (PFC) and hippocampal (HPC) tissue from Df(16)A+/− mice, a model of the 22q11.2 deletion syndrome. Proteomic
results were compared with previous transcriptomic proﬁling studies of the same brain regions. The aim was to investigate how the
combined effect of the 22q11.2 deletion and the corresponding miRNA dysregulation affects the cell biology at the systems level.
The proteomic brain proﬁling analysis revealed PFC and HPC changes in various molecular pathways associated with chromatin
remodelling and RNA transcription, indicative of an epigenetic component of the 22q11.2DS. Further, alterations in glycolysis/
gluconeogenesis, mitochondrial function and lipid biosynthesis were identiﬁed. Metabonomic proﬁling substantiated the
proteomic ﬁndings by identifying changes in 22q11.2 deletion syndrome (22q11.2DS)-related pathways, such as changes in
ceramide phosphoethanolamines, sphingomyelin, carnitines, tyrosine derivates and panthothenic acid. The proteomic ﬁndings
were conﬁrmed using selected reaction monitoring mass spectrometry, validating decreased levels of several proteins encoded on
22q11.2, increased levels of the computationally predicted putative miR-185 targets UDP-N-acetylglucosamine-peptide N-
acetylglucosaminyltransferase 110 kDa subunit (OGT1) and kinesin heavy chain isoform 5A and alterations in the non-miR-185
targets serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform, neuroﬁlament light chain and vesicular
glutamate transporter 1. Furthermore, alterations in the proteins associated with mammalian target of rapamycin signalling were
detected in the PFC and with glutamatergic signalling in the hippocampus. Based on the proteomic and metabonomic ﬁndings, we
were able to develop a schematic model summarizing the most prominent molecular network ﬁndings in the Df(16)A+/− mouse.
Interestingly, the implicated pathways can be linked to one of the most consistent and strongest proteomic candidates, (OGT1),
which is a predicted miR-185 target. Our results provide novel insights into system-biological mechanisms associated with the
22q11DS, which may be linked to cognitive dysfunction and an increased risk to develop schizophrenia. Further investigation of
these pathways could help to identify novel drug targets for the treatment of schizophrenia.
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INTRODUCTION
Hemizygous deletions in chromosome 22q11.2 occur predomi-
nately de novo and cause a deletion syndrome (22q11.2DS),
characterized by a broad spectrum of physical and mental
manifestations with a variable phenotype. The syndrome has an
incidence of 1 in 2000–4000 live births. The physical phenotype is
characterized by variably penetrant craniofacial and cardiovascular
anomalies, immunodeﬁciency, short stature and hypocalcaemia.
Furthermore, deletion carriers typically present with a range of
behavioural and cognitive deﬁcits and 25–30% develop schizo-
phrenia during adolescence or early adulthood.1 22q11.2 dele-
tions account for 1–2% of sporadic schizophrenia cases,
exemplifying the role of rare mutations in disease susceptibility.
Importantly, there are no major clinical differences in the core
schizophrenia phenotype between individuals with schizophrenia
who are 22q11.2 microdeletion carriers and those with an
idiopathic disease onset.2 A 1.5-Mb critical region, which confers
haplo-insufﬁciency of 27 genes,3,4 including the candidate
schizophrenia susceptibility genes (proline dehydrogenase
(PRODH), catechol-O-methyltransferase (COMT) and DHHC palmi-
toyltransferase (ZDHCC8)), is largely conserved on mouse chromo-
some 16. This has facilitated generation of mouse models of the
human 22q11DS, carrying hemizygous deletions in the syntenic
region of chromosome 16. One of the best characterized models is
the Df(16)A+/− mouse, which carries a hemizygous 1.3-Mb
chromosomal deﬁciency on chromosome 16 (Df(16)A), encom-
passing 27 genes, which is syntenic to the minimal 1.5-Mb human
22q11.2 deletion.5 These mice develop deﬁcits in spatial working
memory, sensorimotor gating and fear conditioning as well as
presenting with hyperactive behaviour.5,6 In addition, they show
abnormalities in synaptic connectivity of hippocampal and cortical
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neurons, including a lower density of dendritic spines and
glutamatergic synapses and altered synaptic plasticity.7
Studies that have examined the effect of Df(16)A on transcrip-
tional networks revealed downregulation of microRNA (miRNA)
transcripts,5,8 resulting from the combined effect of two disrupted
genes (Dgcr8 and miR-185) in the critical region. Dgcr8 hemi-
zygosity leads to dysregulation in the production of up to 20% of
all miRNAs, while miR-185 levels are reduced by 70–80% owing to
a combined effect with the Dgcr8 hemizygosity,9 which leads to an
impaired maturation of the pri-miR-185 transcript. Based on the
transcriptional proﬁling, the most robust miRNA target was a
novel neuronal regulatory gene 2310044H10Rik/Mirta22, which
was conﬁrmed to be speciﬁc for miR-185 and has been followed
up in functional studies. It was shown that this gene encodes a
protein, which is located in the Golgi apparatus and in vesicles and
tubular-like extensions of dendrites, mediating at least some of
the effects of the 22q11.2 deletions on dendrite and spine
formation.10
To date, no other direct miRNA targets have been reported for
the 22q11.2DS and it is still not known how the reported
transcriptomic5,11 alterations affect cell biology at the proteomic
and metabonomic level. In the disease pathology, proteomic and
metabonomic networks are likely to be regulated through the
combined interactions of the 22q11.2 deletion gene products,
which involve the hemizygosity of four transcription factors and
disruption of miRNA-regulated targets. This may involve dysregu-
lation of other transcription factors, chromosome remodelling
elements or changes in the expression of signalling proteins. Also,
secondary compensation effects might have a role. Here we have
carried out a combined shotgun proteomic and metabonomic
proﬁling analysis of brain tissue from Df(16)A+/− mice to
investigate the combined effects of miRNA dysregulation and
disruption of genes residing in the 22q11.2 region. Our results
provide novel insights towards a better understanding of the
molecular pathophysiology of psychiatric disorders and cognitive
dysfunction.
MATERIALS AND METHODS
For more detailed information, please refer to Supplementary Methods. A
ﬂowchart of the molecular proﬁling methods can be found in
Supplementary Figure S1.
Animals
The Df(16)A+/− mice were produced and bred at Columbia University (New
York, NY, USA) as described previously.5 Eight-week-old male mice were
used for the analyses. Mutant mice carry a hemizygous 1.3-Mb
chromosomal deﬁciency (Df(16)A+/− ), which ranges from Dgcr2 to the
Hira gene and encompasses a segment syntenic to the 1.5-Mb human
22q11.2 deletion, including 27 protein-coding genes. All animal proce-
dures were performed according to protocols approved by the Columbia
University Institutional Animal Care and Use Committee under federal and
state regulations.
Multiplex immunoassay proﬁling
Serum samples from 11 Df(16)A+/− and 10 wild-type mice (cohort 1) were
analysed randomized and blinded using a multianalyte proﬁling platform,
comprising multiplexed immunoassays for 58 analytes (Supplementary
Table S1) in a Clinical Laboratory Improved Amendments (CLIA)-certiﬁed
laboratory at Myriad-RBM (Austin, TX, USA) as described previously.12,13
Data quality was assessed via principal component analysis (PCA), data
were checked for normality and signiﬁcance analysis of mircroarray14 was
performed.
Metabonomics
Metabonomic sample preparation and proﬁling of prefrontal cortical (PFC)
and hippocampal (HPC) tissues from 11 Df(16)A+/− and 10 wild-type mice
(cohort 1) was performed as described previously.15 In brief, tissue samples
were prepared using a two-step process based on extraction into ‘aqueous’
and ‘organic’ phases for polar and nonpolar metabolites. Quality-control
samples were prepared by combining an aliquot from each study sample
to produce a representative sample, which was used for column
conditioning and data quality assessment as described by Want et al.15
Aqueous extracts were analysed via nano-ultra-performance liquid
chromatography–mass spectrometry (UPLC-MS) analysis using a Waters
XEVO G2 Q-TOF mass spectrometer coupled online to an Acquity UPLC-MS
system (Waters, Milford, MA, USA). Metabolites were separated using a
2.1 × 100 mm2 (1.7 μm) HSS T3 Acquity column, and acquisition was
performed in both positive ion mode and negative ion mode. Quality-
control samples were injected 10 times at the start of the analytical batch
in order to condition the column, and then after every 10 samples
throughout the run to assess instrument stability. Samples were run
randomized and blinded. Data were processed using the freeware
XCMS16,17 using standard parameters. The output consisted of a matrix
of metabolite feature m/z, retention time and intensity values, which was
imported into SIMCA-P for multivariate analysis to check data quality and
sample outliers. Data were normalized, ﬁltered and checked for normality
prior statistical analysis. P-values were determined using Wilcoxon’s
signed-rank test and corrected to control for multiple hypothesis testing
(Benjamini–Hochberg).18 Ratios were calculated for each analyte as the
mean intensity values of Df(16)A+/− mice divided by those of wild-type
littermates.
Proteomics
For more detailed information, please refer to Supplementary Methods.
Sample preparation and study design
PFC and HPC brain tissues from Df(16)A+/− and wild-type mice were
prepared using total lysis protein extraction19,20 combined with either in-
solution (two independent cohorts; cohort 1 (PFC and HPC): 11 Df(16)A+/−
vs 10 wild-type mice, cohort 2 (PFC): 13 Df(16)A+/− vs 13 wild-type mice) or
in-gel tryptic digestion ((PFC): 20 Df(16)A+/− and 21 wild-type mice,
combined from both cohorts to increase statistical power, proteome
coverage and avoid sample extraction biases). Samples were subsequently
analysed using label-free LC-MSE mass spectrometry, enabling unbiased
protein identiﬁcation and quantiﬁcation. Mass spectrometrical sample
preparation, label-free LC-MSE analysis and selected reaction monitoring
(SRM) analysis were performed blinded and randomized. Sample size was
chosen based on previous experiments using FC and HPC brain tissues and
proteomic guidelines. In all, 8–10 animals per group are sufﬁcient for the
proteomic shotgun discovery phase. Power calculations using MSstats
showed that to achieve a fold change of 15% with 0.8 power 10 sample are
needed. The validity of the results was further proven in 20 Df(16)A+/− and
20 wild-type mice using highly sensitive and robust label-based SRM mass
spectrometry.
Label-free LC-MSE analysis of PFC and HPC tissue
Brain tissue samples were analysed individually in technical duplicates
using a splitless UPLC (10 kpsi nanoAcquity; Waters) coupled online to a
Waters Q-TOF Premier mass spectrometer. Data were acquired in
expression mode (MSE). The procedure, quality assessment and
data processing were performed as described previously.21 LC-MSE data
were processed using the ProteinLynx Global Server (PLGS) v.2.4. (Waters)
and Rosetta Elucidator v.3.3 (Rosetta Biosoftware, Seattle, WA, USA)
was used for time and mass/charge alignment of mass spectrometric data.
The Swiss-Prot mouse reference (March, 2013) proteome was used for
protein identiﬁcation searches. Only peptides detected in both
replicates and in 480% of samples were included in further analysis.
Protein abundance changes were determined using the MSstats package22
based on linear mixed-effects models, which views peptides mapped to
the same protein as replicate measurements of protein abundance,
following log2 transformation and exclusion of peptide intensity values
that were 43 s.d. from the mean of each group. The MSstats package
included quality assessment and PCA on the raw data was carried out to
detect data outliers. The P-values were adjusted to control the false-
discovery rate at a cutoff of 0.05 following the Benjamini–Hochberg
procedure.23
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Label-based SRM mass spectrometry
Digested FC and HPC proteomes (20 Df(16)A+/− and 20 wild-type mice),
prepared using in-solution digestion from total lysates, were analysed
using targeted SRM mass spectrometry on a Xevo TQ-S mass spectrometer
(Waters) coupled to a nanoAcquity UPLC system (Waters) as described
previously.13,20,24 Multiplex SRM assays were developed using a high-
throughput strategy.25 Physiochemical criteria for selecting tryptic
peptides were based on peptide count, uniqueness and quality of
transitions. Transitions were selected based on software internal
predictions, discovery proteomics data and spectral data (NIST spectral
libraries26) and calculated using Skyline version 1.2.0.3425.27 Quantitative
SRM measurements comparing abundance levels of 40 proteins between
Df(A)16+/− mice and wild-type littermates were performed in scheduled
SRM acquisition mode. Heavy isotope labelled peptide versions
(JPT Peptide Technologies, Berlin, Germany) were spiked in the peptide
mixture for accurate quantiﬁcation and identiﬁcation. For each peptide, at
least three transitions were monitored for the heavy and light versions. The
ﬁnal transitions can be found in Supplementary Table S2. Samples were
run blinded, randomized and blocked28 in triplicates, and blanks and
quality-control peptide injections (yeast alcohol dehydrogenase)24 were
run alternating after each biological replicate. Resulting SRM data were
analysed using Skyline and statistical analysis, testing for differential
abundance among Df(A)16+/− and wild-type mice, was conducted using
SRMstats23 with the ‘expanded technical replication’ setting. Data quality
was checked using quality plots in the MSstats package and by employing
PCA on the raw data. P-values were corrected to control for multiple
hypothesis testing (Benjamini–Hochberg).18
RESULTS
Serum characterization—quantitative serum immunoassay
proﬁling
Immunodeﬁciency is one of the key features of the 22q11.2DS, but
the degree and spectrum of severity varies widely. A large number
of studies have provided evidence suggestive of an immunolo-
gical component of schizophrenia29 and other psychiatric dis-
orders.30,31 We hypothesized that immune dysfunction, as
reﬂected in the levels of immune and metabolic circulation
markers, may contribute to the elevated risk of schizophrenia in
the 22q11.2DS.32 Analysis of 58 such markers (Supplementary
Table S1) in the serum of the Df(16)A+/− mouse using a multiplex
immunoassay platform resulted in the identiﬁcation of a sign-
iﬁcant decrease in matrix metalloproteinase 9 (MMP-9; ratio = 0.74,
P= 0.039, P* = 0.20) in the Df(16)A+/− (n= 11) compared with wild-
type (n= 10) mice.
Brain characterization—quantitative proteomics
In the proteomic discovery phase, shotgun proﬁling of PFC and
HPC tissue was carried out to identify proteins differentially
expressed in the Df(16)A+/− mouse model compared with
wild-type mice. The main aim was to identify affected protein
networks that might contribute to the development of psychiatric
and cognitive phenotypes in the 22q11.2DS, as well as novel
miR-185 targets. We focused on the PFC and HPC because these
brain regions have previously been characterized at the tran-
scriptomic level5,11 and are implicated in the pathology of various
psychiatric disorders. Special emphasis was placed on the PFC as
the most extensively characterized brain region in the Df(16)A+/−
mouse.5,11 Total lysis extracts from PFC tissues of two independent
cohorts of Df(16)A+/− mice (11 Df(16)A+/− vs 10 wild-type / 13 Df
(16)A+/− vs 13 wild-type) were analysed, as well as from the HPC of
one of the cohorts (11 Df(16)A+/− vs 10 wild-type). Additionally,
PFC tissue of both cohorts were combined (n= 40) and prepared
with a different gel-based procedure to increase proteome
coverage and statistical power. Shotgun proﬁling analysis resulted
in the identiﬁcation of 578 distinct proteins (9605 peptides) in the
PFC (cohort 1) of which 59 proteins showed signiﬁcant genotypic
differences (P*o0.05). Likewise, 715 distinct proteins (14 334
peptides) (cohort 2) were identiﬁed in cohort 2, with 186 proteins
showing abundance differences between genotypes. In total, 552
distinct proteins (11 193 peptides) were identiﬁed in the
combined cohorts and 104 of these had signiﬁcantly changed
protein levels. In the HPC, we identiﬁed 570 distinct proteins (8934
peptides) of which 63 were signiﬁcantly different in the mutant
mice (Supplementary Table S3).
In order to identify robust alterations of Df(16)A+/− hemizyg-
osity, we cross-compared all proteomic proﬁling studies among
each other and to previous transcriptomic proﬁling studies5,11 of
the Df(16)A+/− mice (Figure 1a). Most consistently, we found an
average decrease of 20% in septin 5 levels (Figure 1d), a protein
encoded in the 22q11.2DS critical region. In the case of other
22q11.2DS encoded proteins, we detected a reduction in the
levels of protein DGCR14 (ES2EL) (ratio = 0.85, P= 8.2 × 10− 6,
1 peptide) in one of the proteomic cohorts. We further detected
a 30% increase in the levels of the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) in the Df(16)A+/− mice. Two
mini-cassettes of the Hprt gene are part of the viral transfection
vector where they serve as a positive selection marker for
successful recombination and deletion of the 22q11.2 critical
region. The identiﬁed changes in these proteins substantiate the
technical robustness of our proteomic platform. All other
22q11.2DS-encoded proteins, which could serve as positive
controls, were below the detection limit, probably owing to low
or absent expression in the brain.33
Other identiﬁed proteins, which showed alterations in abun-
dance, are either primary or secondary effects of abnormal miRNA
metabolism or hemizygosity of 22q11.2 genes. For example, we
identiﬁed a decrease in glutathione S-transferase Mu7 (GSTM7) in
three of the proteomic studies, which could be a secondary effect
of the Txnrd2 (thioredoxin reductase 2) hemizygosity. Both
proteins have been implicated in the regulation of the intracellular
redox environment.34–37 Furthermore, we discovered robust
decreases of mitochondrial proteins (cytochrome c oxidase
subunit 5B, mitochondrial (COX5B), NADH-ubiquinone oxidore-
ductase chain 4 (NU4M)). A possible reason for these alterations is
the involvement of several 22q11.2 genes (Prodh, Comt, Txtp,
Slc25a1) in mitochondrial function. Indeed, using the IPA software,
we conﬁrmed that ‘mitochondrial dysfunction’ was a common
pathway affected across all proﬁling studies (Figure 1c).
In order to identify proteins that might be upregulated owing to
miR-185 hemizygosity, we analysed all upregulated detected
proteins using bioinformatic miRNA target prediction tools (MirDB,
Targetscan, MirBase, DIANA), which were based on thermody-
namics (DIANA), seed complementarity (Targetscan) or support
vector machines (MirDB). Potential miR-185 targets are disk large
homolog 2 (DLG2), AP2-associated protein kinase 1 (AAK1),
sodium/potassium-transporting ATPase subunit alpha-3 (AT1A3),
O-GlcNAc transferase subunit p110 (OGT1) and protein bassoon
(BSN), which were found to be upregulated at the proteomic and
transcriptomic levels.5
We were not able to identify a signiﬁcant increase in
sarcoplasmatic/endoplasmic reticulum calcium ATPase 2 (SERCA2
—Atp2a2), another recently proposed target of 22q11.2DS-
associated miRNA dysregulation,38 in any of our proteomic
screens. This is consistent with Fenelon et al.,11 who failed to
conﬁrm a change in the transcript and protein levels of Atp2a2.
Remarkably, the differentially expressed proteins showed an
overall increase in abundance levels across all FC proteomic
studies (Figure 1b), which is likely owing to a decrease in about
20% of the miRNAs5 (including miR-185) and subsequent
upregulation of targets. This ﬁnding is consistent with the
transcriptomic proﬁling study by Fenelon et al.11 On the other
hand, the HPC proteome showed a trend towards downregulation
of differentially expressed proteins. Because of the lack of
replication studies, further conﬁrmation of the opposing changes
in the HPC is needed. Nevertheless, the results are consistent with
reported miRNA changes in PFC and HPC identiﬁed through
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transcriptomic proﬁling, as nearly twice the number of miRNAs
were found to be decreased in the PFC (59 miRNAs) than in the
HPC (30 miRNAs).5
In silico analysis revealed an overrepresentation of developmen-
tally regulated pathways related to nucleosome and chromatin
assembly and chromatin-level regulation across all PFC proteomic
studies (Figure 2). Further pathway analysis using the IPA software
allowed us to identify overlaps between canonical pathways. The
proteomic alterations were associated with the canonical path-
ways ‘glycolysis I’, ‘gluconeogenesis’ and ‘mitochondrial dysfunc-
tion’ (Figure 1c) in the PFC and ‘Rho signalling’ in the HPC, which
was also reﬂected in the enrichment analysis.
Brain characterization—quantitative metabonomics
We next carried out metabonomic proﬁling of PFC and HPC
tissues from the Df(16)A+/− mouse in order to determine whether
the above changes in proteins could be linked to alterations in
metabolites. Therefore, after the initial identiﬁcation of a
metabolite candidate, the sample was re-run and the peaks were
subjected to fragmentation in an MS/MS experiment. Identiﬁca-
tion of a speciﬁc metabolite was accomplished though compar-
ison of the fragmentation pattern of a candidate metabolite with
the known MS/MS fragmentation pattern in public and in-house
databases. This analysis showed signiﬁcant changes in 21 m/z-
retention time pairs in the PFC, and we were able to identify 7 of
Figure 1. (a) Venn diagrams of the overlap of all identiﬁed proteins (left) and of all signiﬁcantly altered proteins (right) identiﬁed in label-free
LC-MSE (liquid chromatography–mass spectrometry) proteomic proﬁling studies of Df(16)A+/− mice compared with wild-type mice
(Supplementary Table S4 for full list). (b) Percentages of signiﬁcantly increased (red) and decreased (green) proteins in Df(16)A+/− mice across
all proteomic studies. Mean percentages show signiﬁcantly increased protein levels in the prefrontal cortex (PFC; po0.05, t-test). PFC
combined are samples from both cohorts combined and in-gel digested (see Material and methods). As the hippocampal (HPC) was only
investigated from one cohort, signiﬁcant levels could not be established. (c) Top ingenuity pathway analysis: altered pathways in the PFC and
HPC. (d) Detailed information of the overlapping proteins identiﬁed as signiﬁcantly changing across all proteomic screens. Proteins were
sorted by the number of proteomic studies in which they have been detected as signiﬁcantly altered. Only proteins with a mean ratio of41.1
or o0.9 across all identiﬁed studies are displayed. P-values were determined using MSstats and corrected to control for multiple hypothesis
testing after Benjamini–Hochberg.114 (Supplementary Table S3 for full information). Proteins identiﬁed by one peptide (italic) were included if
they were overlapping between the proteomic screens. Results were compared with the transcriptomic results using Affymetrix chips
published by Stark et al.5 and Feneleon et al.11 Stark reported 716 transcripts altered in the FC and 85 transcripts in the HPC (false-discovery
rate= 0.01). Signiﬁcantly changed transcripts are marked with an▲ and▼ according to their reported fold change direction in comparison
to wild-type mice. Four different bioinformatic miRNA target prediction tools were used to assess if the upregulated proteins are potential Mir-
185 targets. Xof4, predicted in X of the four predictions; D, downregulation; PC, positive control.
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these metabolites via MS/MS fragmentation. In the HPC, we
detected 27 signiﬁcantly changed m/z-retention time pairs, which
we could match to 12 metabolites using metabolome databases
and identiﬁed 4 via MS/MS fragmentation (Table 1, Supplementary
Table S5). The most signiﬁcant change in the PFC was a decrease
in ceramide phosphoethanolamine (SP0302), which is a sphingo-
myelin analog. SP0302 may be linked to the hemizygosity of the
ZDHHC8 palmitoyltransferase in the Df(16)A+/− mouse, as
palmitoyl-CoA is a precursor in the ceramide synthesis. Alongside,
further ceramides were found to be decreased in the PFC and
S-palmitoyl-L-cysteine was decreased in the HPC. In the HPC, we
also found that sphingomyelin (SM(d17:1/24:1) was the most
signiﬁcantly increased metabolite (ratio = 1.72, P= 0.031). We were
able to validate sphingomyelin’s databank identiﬁcation using
tandem MS/MS. We detected changes in further lipids such as
phosphatidylcholines and glycerolipids, which reﬂect the
changes in lipid metabolism found in the proteomic pathway
analysis of Df(16)A+/− mice (Figure 2). In addition, several
carnitines, which have a role in fatty acid metabolism, were found
to be decreased (Table 1). Furthermore, proteomic abnormalities
in aromatic amino acids could be conﬁrmed via metabonomic
proﬁling, detecting changes in different tyrosine derivates in both
regions (N-stearoyl tyrosine and metyrosine). Although we were
not able to validate the identiﬁcation of these metabolites using
MS/MS, their changes were reﬂected in the protein set enrichment
analysis of the HPC ‘aromatic amino-acid family metabolic
process’. A decrease in panthothenic acid—essential in the
synthesis of coenzyme-A (CoA)—was also reﬂected in the
proteomic pathway analysis with CoA biosynthesis being affected
in cohort 1, where we found increased levels of two of the key
enzymes in this pathway.
Figure 2. Signiﬁcantly enriched pathways identiﬁed by gene set enrichment analysis using GOstats (proteins per pathway 43). The top 15
signiﬁcant Gene Ontotlogy (GO) terms are displayed. GO terms falling into the category of chromosomal regulation are highlighted in grey.
A full colour version of this ﬁgure is available at the Molecular Psychiatry journal online.
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Proteomic validation
We developed highly speciﬁc and sensitive targeted SRM assays in
order to follow-up and validate alterations identiﬁed in the
proteomic discovery phase. We assayed for potential miRNA
targets (OGT1, ADA10) as well as altered proteins identiﬁed in the
LC-MSE proﬁling approach (PP2BC, NRDC). The inclusion of
the miR-185 targets was based on LC-MSE analysis, bioinformatic
predictions and the shotgun proteomics analysis-derived in silico
pathway analysis. We further included 6 of the 27 22q11.2 gene
products to determine whether or not the mRNA changes are
reﬂected at the protein level and could serve as potential positive
controls. The vesicular glutamate transporter 1 (VGLU1) was
included based on evidence obtained from the transcriptomic
screen where VGLU1 was one of the three transcripts found to be
signiﬁcantly upregulated in both PFC and HPC.5 Unfortunately, we
were not able to develop assays for DLG2 and BSN owing to assay
design issues. We further extended the validation screen to
include proteins of pathways that have been implicated in some
of the major symptoms observed in 22q11.2DS. This included the
mammalian target of rapamycin (mTOR) signalling pathway,
which has been linked to autism-like behaviour, cognitive function
and glutamatergic signalling. Details of the composition of the
multiplex assay can be found in Table 2.
The SRM analysis (Table 2) validated the expected decrease in
all the ﬁve tested 22q11.2 gene products and an increase of the
HPRT peptides from the vector cassette, showing the technical
robustness of the developed method. Importantly, SRM conﬁrmed
an increase in the miR-185-target OGT1 in PFC and HPC tissue.
Alterations of OGT1 have been identiﬁed in the transcriptomics5
and in proteomics (Figure 1) high-throughput screens of the PFC.
The OGT1 enzyme exhibits protein N-acetylglucosaminyltransfer-
ase activity, which leads to attachment of O-GlcNAc onto
intracellular proteins.39 Furthermore, we were able to validate an
increase in levels of the glycogen synthase kinase-3 beta (GSK3b)
and kinesin heavy chain isoform 5A (KIF5A), a microtubule-depen-
dent molecular motor that is important for neuronal functions
especially for GABAA receptor transport.
40 Similar to the tran-
scriptomic and PROTEOMIC proﬁling analyses, we did not ﬁnd
altered levels of the miR-185 target transforming protein RhoA
(RHOA). This might be due to secondary regulation caused by the
hemizygous genes or downregulated miRNA that might involve
alterations in transcriptional levels.
Further validated proteins were serine/threonine protein
phosphatase 2B catalytic subunit gamma isoform (PP2BC), the
neuroﬁlament light polypeptide (NFL) and VGLU1. The latter was
one of the only three proteins found in the transcriptomic screen
in both PFC and HPC. The extracellular signal–regulated kinase
(ERK) pathway was most signiﬁcantly affected in the PFC, while
abnormal glutamatergic signalling was predominately found in
the HPC. The latter ﬁnding is consistent with published
transcriptomic proﬁling results from the Df(16)A+/− mice.5
DISCUSSION
To the best of our knowledge, this study represents the ﬁrst
comprehensive quantitative proteomic and metabonomic character-
ization of a 22q11.2DS mouse model. We assume that the phenotype
of this disease model is due to cumulative effects of abnormal
miRNA regulation and hemizygosity of genes residing within the
22q11.2 chromosome region, which requires analysis on the systems
level rather than by targeting the effects of individual genes.41–43
Multiplex immunoassay proﬁling analysis identiﬁed altered
serum levels of only one protein, the endopeptidase MMP-9,
which has been implicated in many pathological conditions such
as cancer, cardiovascular disease,44 amyotrophic lateral sclerosis45
and stroke.46,47 Recently, MMP-9 has been reported to have a role
in the plasticity of the central nervous system48 by regulating the
activity of PFC.49 A functional polymorphism of the MMP-9 gene in
schizophrenia50 and bipolar disorder type II51 has also been
reported. The identiﬁed alterations might serve as surrogate
readouts for the psychiatric comorbidities in the 22q11.2DS and
help to elucidate the molecular mechanisms of the immunode-
ﬁciency in 22q11.2DS patients.
The proteomic brain proﬁling analysis revealed PFC and HPC
changes in various molecular pathways associated with chromatin
remodelling and RNA transcription, indicative of an epigenetic
component of 22q11.2DS. Recently, it has been shown that
developmentally regulated genes involved in chromatin remodel-
ling are overrepresented among targets of de novo mutations in
schizophrenia.52,53 Therefore, this study highlights a possible
contribution of chromatin remodelling in the manifestation of the
psychiatric and cognitive phenotype in 22q11.2DS. Other asso-
ciated pathways were glycolysis, gluconeogenesis, lipid biosynth-
esis and the mitochondrial transport chain. Effects on the latter
two pathways were also reﬂected in the transcriptomic enrich-
ment analysis of the Df(16)A+/− mouse5 and together with lipid
metabolism have frequently been linked to psychiatric
conditions.54,55 Altered levels of sphingomyelin and ceramide
have been reported in erythrocytes and postmortem brain tissues
of schizophrenic patients.56
Based on the proteomic and metabonomic ﬁndings, we created
a schematic model summarizing the most prominent molecular
network ﬁndings in the Df(16)A+/− mouse. Interestingly, all
implicated pathways can be linked through one of the most
consistent and strongest proteomic candidates, (OGT1), which is a
predicted miR-185 target (Figure 3).
OGT1 adds single terminal N-actylglucosamine (O-GlcNAc)
residues to serine/threonine residues of speciﬁc target
proteins.39,57 This represents a crucial signalling modiﬁcation
relevant for cellular functions, such as epigenetic regulation,
transcription activation processes,58,59 chromatin remodelling,60
translation, proteasomal degradation, signal transduction and
stress responses.61 Cellular substrates recognized by OGT1 are
mostly present in macromolecular complexes, such as nuclear
pores,62–65 the transcriptional machinery66–68 and vesicle docking
components.69–72 Consistently, we identiﬁed abnormalities in
biological functions associated with these complexes in the Df
(16)A+/− brain and most of these were found in the PFC.
Interestingly, we identiﬁed robust alterations of several histone
proteins in the Df(16)A+/− mouse model (Figure 1d). O-GlcNAcyla-
tion occurs on all four core-nucleosomal histone proteins (H2A,
H2B, H3 and H4).73 However, such chromatin and transcriptional-
level abnormalities could also be due to the hemizygosity for four
transcription factors (for example, Tbx1, Hira) in the Df(16)A+/−
mouse. Abnormalities in glycosylation have already been postu-
lated to occur in the Df(16)A+/− mouse by a bioinformatic
enrichment analysis, which found coordinated dysregulation of
Golgi-related putative miR-185 targets in the Df(16)A+/− mouse.9
Furthermore, the miR-185 target Mirta22 has been localized to the
Golgi apparatus. This is the ﬁrst study to suggest that changes in
OGT activity may be linked to the above glycosylation alterations.
This is also supported by the fact that in silico analysis of the 25
identiﬁed human OGT interacting proteins showed an enrichment
of intra Golgi-vesicle-mediated transport and vitamin biosynthetic
processes.74 Also, bioinformatic analysis of an OGT-interactome
substantiated the role of OGT in transcriptional regulation.74 A
potential role for O-GlcNAcylation in modifying synaptic efﬁcacy
and cognition has previously been suggested.75 O-GlcNAcylation
of AMPA receptors GluA2 has been linked to long-term depression
in HPC synapses.76 OGT1 is also involved in mitochondrial
function,77 consistent with the ﬁnding of alterations in the levels
of mitochondrial proteins in this study. Overexpression of OGT1
leads to decreases in proteins involved in the respiratory chain
and the TCA cycle,77 as well as altered mitochondrial morphology.
The majority of O-GlcNAc-modiﬁed proteins are soluble nuclear or
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cytoplasmic proteins that are modiﬁed in response to cellular or
environmental cues, such as growth factors, signalling molecules,
glucose and other nutrient ﬂuxes and stressors. O-GlcNAcylation
has also been implicated in the aetiology of human disorders,
including type II-diabetes,78 Alzheimer’s disease79 and cancer.80
Notably, O-GlcNAcylation has also been shown to be a negative
regulator of insulin signalling.81 Transgenic mice overexpressing
OGT in muscle and fat show elevated insulin levels and insulin
resistance.81,82 Interestingly, schizophrenia patients show an
increased prevalence of diabetes, impaired glucose tolerance83
and metabolic syndrome.84 Similarly, molecular analyses of
postmortem brain tissues and blood cells have substantiated
these ﬁndings.85–87 We also conﬁrmed changes in GSK3beta and
KIF5A, a microtubule-dependent molecular motor that is impor-
tant for neuronal function, especially for GABAA receptor
transport.40 In contrast, we did not ﬁnd changes in the known
miRNA target RHOA in any of the omics experiments. This might
be due to the secondary effects of 22q11.2-encoded proteins.
Further novel candidate miRNA targets implicated in both this and
previous transcriptomic studies5,9 include BSN, VAMP2, AAK1
and DLG2.
We were also able to validate the increased levels of PP2BC and
NFL in the model. PP2BC is involved in synaptic plasticity and has
already been shown to be associated with schizophrenia in
genome-wide association studies,88,89 via genome-wide DNA
methylation analysis90 and transcriptomic studies.91 As PP2BC
phosphorylates proteins on serine or threonine residues, it may
have a role in the extensive crosstalk between O-GlcNAcylation
and phosphorylation involved in cellular signalling.92 Interestingly,
VGLU1 was increased signiﬁcantly in our proteomics and also the
Figure 3. Schematic model summarizing the ﬁndings of the proteomic and metabonomic proﬁling analyses. Green boxes: altered levels of
molecules determined by proteomic or metabonomic proﬁling. Orange boxes: altered pathways determined by in silico pathway analysis
using IPKB or gene set enrichment analysis. Increased levels of O-GlcNAc transferase subunit p110 (OGT1) lead to abnormal O-GlcNAcylation,
which affects chromatin remodelling and transcriptional regulation. Levels of the OGT1 substrate UDP-GlcNac are generated by glycolysis and
gluconeogenesis (both found to be enriched). Both glutamatergic and Ca2+ signalling are mainly affected in the hippocampus (HPC).
(R)= regulates. IPKB, Ingenuity Protein Knowledge Base; PFC, prefrontal cortex.
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transcriptomic (PFC and HPC) screens. This protein has already
been shown to be increased in bipolar disorder and major
depressive disorder93 and decreased in schizophrenia.94
We also tested proteins that have already been implicated at
the pathway level in major psychiatric symptoms observed in
22q11.2DS. The ﬁrst of these was the mTOR pathway, which has
been linked to autism spectrum disorder,95–97 cognition98,99 and
glutamate signalling.100–102 The SRM analysis showed that mTOR
was speciﬁcally affected in the PFC together with changes in the
ERK1/2, PKCG and CAMK2 isoforms, which are essential compo-
nents of NMDAR-related signal transduction. ERK is regulated by
the activity of dopamine, serotonin and glutamate receptors.103
ERK signalling has also been implicated in the mechanism of
action of mood stabilizers104 and antipsychotics105 and has been
shown to be affected in social behaviour106 and autism spectrum
disorder.107–109
In contrast to the above ﬁndings, we found a robust increase in
proteins relating to glutamatergic signalling in the HPC. This is
consistent with the ﬁndings of the transcriptomic proﬁling study
of the Df(16)A+/− mouse, which found upregulation of a multi-
modal gene interaction network in the HPC associated with DLG4
and glutamatergic synapses.5 The HPC has been implicated in the
cognitive deﬁcits in 22q11 as alterations in the gross morphology
of this brain region have been observed in 22q11.2DS
patients,110–112 and this positively correlates with cognitive
impairment.112 Interestingly, PKCG was also found to be increased
in the HPC. Furthermore, O-GlcNAcylation of AMPA receptor
GluA2 is associated with NMDA receptor and PKC-independent
long-term depression in Ca3-Ca1 synapses.113 Therefore, our
ﬁndings of alterations in the levels of OGT1 support the possibility
that disruption of O-GlcNAcylation pathways could be involved in
cognitive dysfunction processes.
In conclusion, this is the ﬁrst system-based study to identify
proteomic and metabonomic abnormalities in a 22q11.2DS mouse
model. The main effects were brain region speciﬁc and involved
proteins associated with chromatin modulation pathways, along
with alterations in lipid and energy metabolism pathways. As one
of the most robust candidates, we were able to identify OGT1, a
potential miR-185 target, and postulated that O-GlcNAc might
have effects on many of the affected pathways. These results
provide further insights into the molecular basis of the synaptic,
circuitry and behavioural deﬁcits of the 22q11.1 mouse model and
potentially of the human syndrome. A shortcoming of this study is
that the employed approaches focus on global changes of FC and
HPC tissue, although these brain regions are comprised of
different subpopulations of brain cells, which might lead to a
dilution of the magnitude of the changes. Further analysis into
these brain regions and of the role of OGT1 in these effects might
help to elucidate its neuronal functions and increase our
understanding of the development and pathogenesis of schizo-
phrenia and other psychiatric disorders in 22q11.2DS and in the
wider population.
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